Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer

August 27th 2020

Allyson Ocean, MD, discusses the encouraging results from the phase II TYME-88-Panc study of SM-88 in patients with advanced pancreatic cancer.

Dr. Mehta on the Role of Biomarkers in Gastric Cancer

August 26th 2020

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm

August 26th 2020

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Pembrolizumab Receives 2 New Approvals Across Oncology in Japan

August 24th 2020

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for the treatment of patients with radically unresectable, advanced, or recurrent esophageal squamous cell carcinoma whose tumors are PD-L1–positive, and at an additional recommended dosage of 400 mg every 6 weeks as an intravenous infusion across all adult indications.

Expert Perspectives on the Identification and Management of Drug-Induced Interstitial Lung Disease

August 24th 2020

Experts share insight on their clinical experience with interstitial lung disease.

Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers

August 22nd 2020

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Rapid Progress in HCC Paradigm Shifts Standards, Sequencing Strategies

August 20th 2020

Bradley G. Somer, MD, discusses shifts in the hepatocellular carcinoma treatment paradigm, pivotal trials that have generated excitement, and sequencing approaches.

Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape

August 20th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.

Atezolizumab/Bevacizumab Approval Leaves Second-Line Questions in HCC

August 20th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of HCC, the approval of atezolizumab/bevacizumab, and other pivotal data in HCC.

Rectal Cancer Treatment Enters an Era of Personalized Medicine

August 19th 2020

Noam VanderWalde, MD, MS, highlights the importance of multidisciplinary care for rectal cancer and few key studies that have impacted treatment.

Research Efforts Abound in HER2-Positive Gastric and GEJ Cancers

August 19th 2020

Rutika J. Mehta, MD, MPH discusses key updates in gastric and gastroesophageal junction management, trials of interest, and the importance of testing for biomarkers.

Pembrolizumab/Chemo Combo Significantly Boosts Survival in Esophageal Cancer

August 19th 2020

Pembrolizumab in combination with chemotherapy significantly improved overall survival and progression-free survival in the frontline treatment of patients with locally advanced or metastatic esophageal cancer.

Liposomal Irinotecan Regimen Pushes Toward Frontline Treatment in Metastatic Pancreatic Cancer

August 18th 2020

Dae Won Kim, MD, discusses the NAPOLI-1 and NAPOLI-3 trials in metastatic pancreatic cancer, as well as the role of PARP inhibitors and remaining challenges in the space.

Modest Gains in Metastatic Pancreatic Cancer Leave Room for Improvement

August 18th 2020

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

Dr. El-Khoueiry on the Frontline Treatment Landscape in HCC

August 17th 2020

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

Dr. Kim on the Evolving Treatment Landscape of Advanced HCC

August 14th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Dr. VanderWalde on Future Research in Rectal Cancer

August 13th 2020

Noam VanderWalde, MD, MS, discusses where future research efforts should focus in rectal cancer.

Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRC

August 12th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Nivolumab Plus Chemotherapy Shows Significant Survival Benefit in Gastric and Esophageal Cancers

August 11th 2020

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma

Adjuvant Nivolumab Significantly Improves DFS in Resected Esophageal or GEJ Cancer

August 11th 2020

Nivolumab, following neoadjuvant chemoradiation and complete surgical resection, resulted in a statistically significant improvement in disease-free survival in patients with resected esophageal or gastroesophageal junction cancer.